Cite

HARVARD Citation

    Arad, N. et al. (2022). Overcoming Barriers to Biosimilar Adoption: Commentary on "Cost to Medicare of Delayed Adalimumab Biosimilar Availability". Clinical pharmacology & therapeutics. 112 (1), pp. 25-27. [Online]. 
  
Back to record